=== Outcome Extract 1 (Efficacy) ===
, Liu SY, Zhou Q, Wu YL. Signal
Transduct Target Ther. 2023 Feb 24;8(1):76. doi: 10.1038/s41392-022-01286-3. PMID: 36823150 Free
PMC article. Clinical Trial.
4. PMID: 36369159
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm
study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with
stages IB-select IIIB resectable non-small cell lung cancer.
Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt
RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doeb

=== Outcome Extract 2 (Safety) ===
, English, French, from 2023
8 articles obtenus : trois articles n’ont pas été sélectionnés, car le stade investigué était IIIB-IV
5 articles sélectionnés et 1 article ajouté par les experts : pas de résultat de nature à faire évoluer les
recommandations internationales
1. PMID: 37236398
Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib
in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3
ADAURA Trial.
John T, Grohé C, Goldman JW, Shepherd FA, de Marinis F, Kato T, Wang Q, Su WC, Choi JH, Sriuranpong
V, Me

=== Outcome Extract 3 (Safety) ===
u Q, Wu YL. Signal
Transduct Target Ther. 2023 Feb 24;8(1):76. doi: 10.1038/s41392-022-01286-3. PMID: 36823150 Free
PMC article. Clinical Trial.
4. PMID: 36369159
Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm
study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with
stages IB-select IIIB resectable non-small cell lung cancer.
Rusch VW, Nicholas A, Patterson GA, Waqar SN, Toloza EM, Haura EB, Raz DJ, Reckamp KL, Merritt
RE, Owen DH, Finley DJ, McNamee CJ, Blasberg JD, Garon EB, Mitchell JD, Doebele RC, Bac

